vimarsana.com

First-line treatment with lutetium Lu 177 dotatate plus long-acting octreotide led to a statistically significant and clinically meaningful improvement in progression-free survival compared with high-dose long-acting octreotide alone in newly diagnosed patients with somatostatin receptor–positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors.

Related Keywords

Jeff Legos ,Novartis ,Oncology Development At Novartis ,Oncology Development ,Gastrointestinal Cancer ,News ,Gi Cancer ,Lutathera ,Phase 3 Netter 2 Trial ,Nct03972488 ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.